Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Nature medicine - 1 Jun 2005

Trkola Alexandra, Kuster Herbert, Rusert Peter, Joos Beda, Fischer Marek, Leemann Christine, Manrique Amapola, Huber Michael, Rehr Manuela, Oxenius Annette, Weber Rainer, Stiegler Gabriela, Vcelar Brigitta, Katinger Hermann, Aceto Leonardo, Günthard Huldrych F

Abstract excerpt

To determine the protective potential of the humoral immune response against HIV-1 in vivo we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in suppressing viral rebound in six acutely and eight chronically HIV-1-infected individuals undergoing interruption of antiretroviral treatment (ART). Only two of eight chronically infected individuals showed evidence of a delay in viral rebound...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal

Share to Chronic Disease

Share to HIV Antibodies

Share to Immunization, Passive

Share to Viral Load

Share to Virus Replication

Source

Identifiers

PMID: 15880120
DOI: 10.1038/nm1244

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.PMID 15880120Read ↗

The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and PreventionSemantic proximity Read ↗

Neutralizing Antibodies Have Limited Effects on the Control of Established HIV-1 Infection In VivoSemantic proximity Read ↗

HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.Semantic proximity Read ↗

T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapySemantic proximity Read ↗

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound.Semantic proximity Read ↗

Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques.Semantic proximity Read ↗

Neutralizing Antibody Responses against Autologous and Heterologous Viruses in Acute versus Chronic Human Immunodeficiency Virus (HIV) Infection: Evidence for a Constraint on the Ability of HIV To Completely Evade Neutralizing Antibody ResponsesSemantic proximity Read ↗

Effects of neutralizing antibodies on escape from CD8+ T-cell responses in HIV-1 infection.Semantic proximity Read ↗

Progress toward active or passive HIV-1 vaccination.Semantic proximity Read ↗

In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10.Semantic proximity Read ↗

Initial HIV-1 Antigen-Specific CD8 + T Cells in Acute HIV-1 Infection Inhibit Transmitted/Founder Virus ReplicationSemantic proximity Read ↗

Antibody-Dependent Enhancement and the Risk of HIV InfectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.